News | Image Guided Radiation Therapy (IGRT) | October 08, 2019

Patient Treatments With ViewRay's MRIdian Linac Begin in New England

Joint cancer program in Boston first in New England to offer MRI-guided radiation therapy

Patient Treatments With ViewRay's MRIdian Linac Begin in New England

October 8, 2019 — ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac System at Dana-Farber/Brigham and Women's Cancer Center. The MRIdian provides for the delivery of radiation therapy to targeted tumors while simultaneously providing continuous magnetic resonance imaging (MRI).

"We will now be able to adapt the therapy to changes in the patient's body such as movement caused by breathing or digestion, to target cancer more accurately and deliver radiation only when the tumor is in the proper position," said Daphne Haas-Kogan, M.D., chair Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center.

The new MRI-guided radiation therapy will be used to treat many different cancer types. Its greatest potential advantage will be in treating soft-tissue tumors – including breast, gastrointestinal, gynecological, prostate, pancreas, sarcoma, and head and neck tumors – and for tumors that are highly mobile, such as lung cancers.

"This new technology offers substantial clinical benefit by providing greater resolution of soft tissue tumors, allowing for more precise tumor targeting and less radiation exposure thus sparing healthy tissue," said Raymond Mak, M.D., lead radiation oncologist for MRI-guided radiation therapy at Dana-Farber/Brigham and Women's Cancer Center. "This cutting-edge technology allows us to personalize and adapt each treatment in ways we never could before."

For more information: www.viewray.com

Related Content

Guerbet Signs Agreement With Icometrix for Exclusive Distribution of Icobrain
News | Neuro Imaging | October 16, 2019
Guerbet announced it has signed an exclusive agreement with Icometrix for the distribution in France, Italy and Brazil...
Subtle Medical Receives FDA 510(k) Clearance for AI-powered SubtleMR
Technology | Artificial Intelligence | October 16, 2019
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtleMR. SubtleMR...
Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Feature | Prostate Cancer | October 16, 2019 | By Jeff Zagoudis
Radiation therapy is an important tool in the clinician’s armamentarium for treatment of localized, early-stage prost
Using Compressed SENSE for faster MRI scans, healthcare providers can transform their radiology workflow.

Using Compressed SENSE for faster MRI scans, healthcare providers can transform their radiology workflow.

Sponsored Content | Case Study | Magnetic Resonance Imaging (MRI) | October 16, 2019
Since the introduction of magnetic resonan...
Videos | Radiation Oncology | October 11, 2019
Lorraine Drapek, DNP, nurse practitioner, radiation oncology, GI service,...
Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI

Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI

Feature | Magnetic Resonance Imaging (MRI) | October 09, 2019 | By Jeff Zagoudis
ProTom International received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radiance 330 proton therapy system
News | Proton Therapy | October 07, 2019
ProTom International received 510(k) clearance from the U.S.
Videos | Prostate Cancer | September 30, 2019
Bill Hartsell, M.D., medical director of the Northwestern Medicine Proton Center in Warrenville, Ill., discusses the
eBook on Hypofractionation in the Age of Value-based Care

eBook on Hypofractionation in the Age of Value-based Care

Sponsored Content | Case Study | Radiation Therapy | September 30, 2019
Hypofractionated and ultrahypofractionated radiation therapy — increasing dose per fraction to enable significantly f